Clinical Trial

Metagenomic Next-Generation Sequencing for the Diagnosis of Fracture-related Infection

Study acronym: METADIAG 2
Completed
View on ClinicalTrials.gov →
Summary
The value of next-generation sequencing (NGS) using Nanopore technology has been demonstrated in the case of diabetic patients' wounds or in prosthetic joint infections. The aim of this study is to demonstrate its relevance as a new diagnostic approach for fracture-related infections (FRI). Bone samples from patient with FRI will be submitted to shotgun metagenomic Next-generation sequencing using Oxford Nanopore Technology (ONT) in order to establish its diagnostic value in this context in comparison with the reference method.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-11-20; most recent amendment 2026-07-06.
Status change: Active, Not Recruiting → Completed 2026-07-06
Trial Details
NCT Number NCT07256405
Lead Sponsor Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Collaborators: Military Teaching Hospital Sainte Anne, Toulon, Institut Hospitalo-Universitaire Méditerranée Infection
Conditions Infection, Fracture, Bone
Enrollment 100 participants
Start Date 2024-03-11
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-07